European port (EU)
The European Union is contradicting world trade rules by putting the interests of big drug companies before the 2 billion people in the world who cannot access essential medicines, according to a new report issued today by three European NGOs.
The report coincides with recent news that India and Brazil are filing a complaint against the European Commission at the WTO after the Netherlands seized anti-HIV and other medicines earlier this year.
The medicines were going from India via Europe to Brazil, Colombia and Nigeria, according to Oxfam International, Health Action International Europe (HAI) and Medicine without Frontiers (MSE).
The report says that, since late 2008, Germany as well as the Netherlands has made customs seizures together totaling 19 shipments of generic medicines bound for developing countries.
The European NGOs say the generic shipments were legitimate under WTO rules.
The EU is increasing pressure on developing country governments to surrender their rights to obtain affordable, generic medicines in order to protect public health, even though these rights are guaranteed under global trade rules, the groups say.
The EU is also insisting on tough new intellectual property rules in bilateral free trade deals that go beyond the WTO’s existing TRIPS agreement.
The EU is pushing these measures that will result in higher medicine prices in developing countries at the same time it is trying to reduce domestic medicine prices.
Twenty-four out of 27 EU Member States have taken steps to implement price controls for medicines.
Elise Ford, head of Oxfam’s EU office told a press conference in Brussels this week: “the EU is guilty of double standards. One rule for the rich and another for the poor. A crackdown on European pharmaceutical prices is happening alongside a concerted effort to further push intellectual property rules that prevent poor countries from buying affordable medicines. "
The EU’s policies are increasing the cost of medicines. This is hitting the poorest people in developing countries disproportionately hard, as 20-60% of their health budgets are spent on medicines.
“Millions of poor people have to pay for medicines out of their own pockets so even a small price rise can make them unaffordable. Europe’s policies are directly responsible for this scandal," Ford said.
Sophie Bloemen, Projects Officer for Health Action International Europe, said: “The EU must accept its moral and legal obligations. There is growing evidence that the EU’s trade agenda is causing severe damage to public health in developing countries."
EuAsiaNews cited her as saying that Dutch authorities argue that the seizure of the medicines was in line with EU patent rules.
The report details a number of other EU policies that are damaging access to medicines in developing countries including:
- promotion of a new global framework to enforce Intellectual Property rules which delay access to generic medicines in developing countries, including through seizures of legitimate medicines;
- obstructing progress at the World Health Organization towards new models of research and development that meet health needs in developing countries; and
- spending on R&D for developing countries that remains insufficient in spite of increases in recent years.
While the EU is increasing funding to improve health care for European citizens, it is denying developing countries the affordable medicines they need to ensure good health, the report says.
Comments